Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
49 patients aged 28 to 81 years old (median age of 55 years old) with relapsed or refractory multiple myeloma (MM) were enrolled in the study. The relapse was diagnosed in 25 (51 %) patients, the refractory disease was determined in 24 (49 %) patients (including primary refractory disease in 14 (28....
Saved in:
Main Authors: | T. A. Мitinа, A. K. Golenkov, E. V. Trifonova, E. V. Kataeva, L. L. Vysotskaya, Yu. B. Chernykh, S. G. Zakharov, K. A. Belousov, A. V. Karaulov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2015-12-01
|
Series: | Онкогематология |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/162 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01) -
PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION
by: R. Yagudina, et al.
Published: (2015-03-01) -
Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01) -
The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2015-10-01) -
Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)